150 related articles for article (PubMed ID: 25566840)
1. [Interplay between marketing authorization and early benefit assessment of drugs].
Beinlich P; Müller-Berghaus J; Sudhop T; Vieths S; Broich K
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Mar; 58(3):227-31. PubMed ID: 25566840
[TBL] [Abstract][Full Text] [Related]
2. [Requirements for drug approval and additional benefits assessment: Regulatory aspects and experiences].
Broich K; Löbker W; Schulte A; Beinlich P; Müller T
Nervenarzt; 2016 Apr; 87(4):376-85. PubMed ID: 27003322
[TBL] [Abstract][Full Text] [Related]
3. [Benefit assessment of drugs].
Kaiser T; Vervölgyi V; Wieseler B
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Mar; 58(3):232-9. PubMed ID: 25566842
[TBL] [Abstract][Full Text] [Related]
4. [Scientific advice by the nationally competent authority and by the EMEA on the conduct of clinical trials].
Dejas-Eckertz P; Schäffner G
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):423-8. PubMed ID: 15830253
[TBL] [Abstract][Full Text] [Related]
5. [Benefit assessment of medical interventions].
Klar R; Vach W
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Mar; 58(3):219. PubMed ID: 25676451
[No Abstract] [Full Text] [Related]
6. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
7. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
8. [Drug assessment: IQWiG, G-BA, and an international comparison].
Glaeske G
Internist (Berl); 2016 Jan; 57(1):94-101. PubMed ID: 26502888
[TBL] [Abstract][Full Text] [Related]
9. [Benefit assessment of operative interventions from the perspective of surgical research].
Hüttner FJ; Ulrich A; Mihaljevic AL; Probst P; Rossion I; Diener MK
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Mar; 58(3):248-55. PubMed ID: 25566844
[TBL] [Abstract][Full Text] [Related]
10. [Experiences and recommendations of the German Federal Institute for Drugs and Medical Devices (BfArM) concerning clinical investigation of medical devices and the evaluation of serious adverse events (SAE)].
Renisch B; Lauer W
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Dec; 57(12):1368-75. PubMed ID: 25376539
[TBL] [Abstract][Full Text] [Related]
11. Effect of Crossover in Oncology Clinical Trials on Evidence Levels in Early Benefit Assessment in Germany.
Isbary G; Staab TR; Amelung VE; Dintsios CM; Iking-Konert C; Nesurini SM; Walter M; Ruof J
Value Health; 2018 Jun; 21(6):698-706. PubMed ID: 29909875
[TBL] [Abstract][Full Text] [Related]
12. [Benefit assessment of medical devices].
Zens Y; Fujita-Rohwerder N; Windeler J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Mar; 58(3):240-7. PubMed ID: 25566843
[TBL] [Abstract][Full Text] [Related]
13. [Educational material as part of risk minimisation].
Heymans L; Huber M; Paeschke N; Palissa H; Keller-Stanislawski B
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2018 Sep; 61(9):1088-1092. PubMed ID: 30083947
[TBL] [Abstract][Full Text] [Related]
14. [Health-related quality of life: a pivotal endpoint in benefit assessment of medical procedures].
Bullinger M; Blome C; Sommer R; Lohrberg D; Augustin M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Mar; 58(3):283-90. PubMed ID: 25589357
[TBL] [Abstract][Full Text] [Related]
15. [Medical devices. Regulatory framework and contribution of the German Federal Institute for Drugs and Medical Devices (BfArM) to the safe application].
Lauer W; Stößlein E; Brinker A; Broich K
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Dec; 57(12):1355-61. PubMed ID: 25370170
[TBL] [Abstract][Full Text] [Related]
16. [Benefit assessment in health services research and epidemiology].
Wegscheider K; Drabik A; Bleich C; Schulz H
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Mar; 58(3):298-307. PubMed ID: 25566839
[TBL] [Abstract][Full Text] [Related]
17. Varying results of early benefit assessment of newly approved pharmaceutical drugs in Germany from 2011 to 2017: A study based on federal joint committee data.
Peinemann F; Labeit A
J Evid Based Med; 2019 Feb; 12(1):9-15. PubMed ID: 30701688
[TBL] [Abstract][Full Text] [Related]
18. [Biostatistical support for decision making in drug licensing and reimbursement exemplified by implications of heterogeneous findings in subgroups of the study population].
Gonnermann A; Kottas M; Koch A
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Mar; 58(3):274-82. PubMed ID: 25566838
[TBL] [Abstract][Full Text] [Related]
19. [From the licensure of vaccines to the recommendation of the Standing Committee on Vaccination in Germany : criteria for the assessment of benefits and risks].
Pfleiderer M; Wichmann O
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Mar; 58(3):263-73. PubMed ID: 25566841
[TBL] [Abstract][Full Text] [Related]
20. [Safety of high risk in vitro diagnostic medical devices : international and national measures].
Halbauer J; Siekmeier R; Funk M
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Jun; 52(6):610-8. PubMed ID: 19421725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
